Cellectar Biosciences Stock Earnings Reports

Cellectar reported a transformational Q1 2026 driven by positive 12-month follow-up data from the Phase IIb CLOVER WaM study of iopofosine I-131 in relapsed/refractory Waldenstrom Macroglobulinemia (WM), an oversubscribed financing package, and advancement of its CLR125 program in triple-negative breast cancer (TNBC). Key clinical highlights for iopofosine: overall response rate (ORR) 83.6%, major response rate (MRR) 61.8%, median duration of response (DOR) 17.8 months, median progression-free survival (PFS) ~13.5–15+ months with >30% of responders maintaining responses beyond 36 months. Management believes these data meet elements supporting eligibility for accelerated approval and plans to initiate a randomized Phase III confirmatory trial (PFS primary endpoint) in late Q4 2026, with a rituximab/cyclophosphamide/dexamethasone (RCD) comparator expected to have PFS in the ~6–8 month range in post-BTKi patients. Financially, the company ended Q1 with $8.3M in cash (pre-financing) and completed an oversubscribed financing structured as $35M upfront plus up to $105M in milestone-based warrants (aggregate potential $140M). Management expects the financing to provide the resources to advance the Phase III trial and fund operations into Q2 2027, subject to milestone achievement and warrant exercise conditions. Operationally, CLR125 (an alpha-emitting radio-conjugate) has dosed initial patients in a Phase Ib TNBC dose-finding study; biodistribution/dosimetry and early efficacy data are expected later in 2026. Key near-term milestones for investors: initiation of the Phase III WM trial (target late Q4 2026), NDA/accelerated approval path timing (management targets potential FDA action in H2 2027 with their timeline assumptions), presentation of subgroup data at ASCO, and early CLR125 clinical readouts. Risks remain typical for clinical-stage biotech: confirmatory trial execution, regulatory review uncertainty, milestone-based financing conditionality, and cash/runway subject to milestone timing and warrant conversion.